Literature DB >> 28404573

Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Xiaohong Cui1, Stuart P Adler2, Mark R Schleiss3, Ravit Arav-Boger4, Gail J Demmler Harrison5, Michael A McVoy6.   

Abstract

Cytomegalovirus (CMV) causes sensorineural hearing loss and developmental disabilities in newborns when infections are acquired in utero Pregnant women may acquire CMV from oral exposure to CMV in urine or saliva from young children. Neutralizing antibodies in maternal saliva have the potential to prevent maternal infection and, in turn, fetal infection. As CMV uses different viral glycoprotein complexes to enter different cell types, the first cells to be infected in the oral cavity could determine the type of antibodies needed to disrupt oral transmission. Antibodies targeting the pentameric complex (PC) should block CMV entry into epithelial cells but not into fibroblasts or Langerhans cells (which do not require the PC for entry), while antibodies targeting glycoprotein complexes gB or gH/gL would be needed to block entry into fibroblasts, Langerhans cells, or other cell types. To assess the potential for antibodies to disrupt oral acquisition, CMV from culture-positive urine samples (uCMV) was used to study cell tropisms and sensitivity to antibody neutralization. uCMV entered epithelial cells poorly compared with the entry into fibroblasts. CMV-hyperimmune globulin or monoclonal antibodies targeting gB, gH/gL, or the PC were incapable of blocking the entry of uCMV into either fibroblasts or epithelial cells. Both phenotypes were lost after one passage in cultured fibroblasts, suggestive of a nongenetic mechanism. These results suggest that uCMV virions have a reversible block to epithelial cell entry. Antibodies may be ineffective in preventing maternal oral CMV acquisition but may limit viral spread in blood or tissues, thereby reducing or preventing fetal infection and disease.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  congenital infection; cytomegalovirus; neutralizing antibodies; vaccine

Mesh:

Substances:

Year:  2017        PMID: 28404573      PMCID: PMC5461377          DOI: 10.1128/CVI.00024-17

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  33 in total

1.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

3.  Detection of cytomegalovirus in urine samples by enzyme-linked immunosorbent assay.

Authors:  J A McKeating; S Stagno; P R Stirk; P D Griffiths
Journal:  J Med Virol       Date:  1985-08       Impact factor: 2.327

4.  Detection of cytomegalovirus by ELISA in urine samples is inhibited by beta 2 microglobulin.

Authors:  J A McKeating; J E Grundy; Z Varghese; P D Griffiths
Journal:  J Med Virol       Date:  1986-04       Impact factor: 2.327

Review 5.  Human papillomavirus oncoproteins: pathways to transformation.

Authors:  Cary A Moody; Laimonis A Laimins
Journal:  Nat Rev Cancer       Date:  2010-07-01       Impact factor: 60.716

6.  Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells.

Authors:  Giuseppe Gerna; Elena Percivalle; Daniele Lilleri; Laura Lozza; Chiara Fornara; Gabriele Hahn; Fausto Baldanti; M Grazia Revello
Journal:  J Gen Virol       Date:  2005-02       Impact factor: 3.891

7.  Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration.

Authors:  Sarah Straschewski; Marco Patrone; Paul Walther; Andrea Gallina; Thomas Mertens; Giada Frascaroli
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

8.  Cytomegalovirus in urine specimens has host beta 2 microglobulin bound to the viral envelope: a mechanism of evading the host immune response?

Authors:  J A McKeating; P D Griffiths; J E Grundy
Journal:  J Gen Virol       Date:  1987-03       Impact factor: 3.891

9.  Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H.

Authors:  L Li; K L Coelingh; W J Britt
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.

Authors:  Xiaohong Cui; Benjamin P Meza; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

View more
  4 in total

1.  Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of In Vitro Screenings.

Authors:  Joseph W Jackson; Trevor J Hancock; Pranay Dogra; Ravi Patel; Ravit Arav-Boger; Angela D Williams; Stephen J Kennel; Jonathan S Wall; Tim E Sparer
Journal:  mSphere       Date:  2019-02-13       Impact factor: 4.389

2.  Inclusion of Antibodies to Cell Culture Media Preserves the Integrity of Genes Encoding RL13 and the Pentameric Complex Components During Fibroblast Passage of Human Cytomegalovirus.

Authors:  Amine Ourahmane; Xiaohong Cui; Li He; Meaghan Catron; Dirk P Dittmer; Ahmed Al Qaffasaa; Mark R Schleiss; Laura Hertel; Michael A McVoy
Journal:  Viruses       Date:  2019-03-05       Impact factor: 5.048

3.  Inclusion of the Guinea Pig Cytomegalovirus Pentameric Complex in a Live Virus Vaccine Aids Efficacy against Congenital Infection but Is Not Essential for Improving Maternal and Neonatal Outcomes.

Authors:  Mark R Schleiss; Claudia Fernández-Alarcón; Nelmary Hernandez-Alvarado; Jian Ben Wang; Adam P Geballe; Michael A McVoy
Journal:  Viruses       Date:  2021-11-26       Impact factor: 5.818

4.  Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts.

Authors:  Nina Reuter; Barbara Kropff; William J Britt; Michael Mach; Marco Thomas
Journal:  Viruses       Date:  2022-01-28       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.